A Lesson to Learn o...
Health Care: Drugs
Geron Corporation (GERN: NASDAQ)
$1.15 0.00 | 0.00%
06/18/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 1.15 |
| 52 Week High | 2.99 |
| 52 Week Low | 0.91 |
| Avg. Daily Vol. (Mil) | 0.72 |
| Beta (3 year) | 2.21 |
| Share Related Items | |
| Mkt Cap (Mil) | 149.99 |
| Shares Out (Mil) | 130.43 |
| Float (Mil) | 128.09 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 11.00 |
| Current Ratio | 12.00 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 67.56 |
| Price/Book | 1.97 |
| Price/Cash Flow | -2.60 |
| Per Share Data | |
| Earnings | -0.48 |
| Sales | 0.02 |
| Book Value | 0.58 |
| Cash Flow | -0.45 |
| Business Summary | |
|---|---|
| Geron Corporation develops therapeutic products for cancer that inhibit telomerase. Its product candidate include Imetelstat, a telomerase inhibitor, which is in Phase II clinical trials. | |
| General Information | |
| 230 Constitution Drive
Menlo Park, CA 94025 |
|
| www.geron.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 105 | |
| CEO: Dr. John A. Scarlett,M.D | |
| Short Interest | |
| Current Month (Mil) | 4.37 |
| Previous Month (Mil) | 4.38 |
| Short Interest Ratio (Days) | 6.90 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -74.90 |
| Return on Investments | -81.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with GERN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- Contributor22 Biopharma Stocks With Br...
- ContributorUnder-$10 Setting Up To Tra...
Latest GERN Headlines from TheStreet
- 8 Stocks Under $10 Soaring Higher 01.31.13 | 03:01 pm
- 5 Stocks Ready to Break Out 01.18.13 | 12:01 pm
- Stocks Slump as U.S. and Eurozone Uncertainties Fester 12.04.12 | 04:12 pm
- Stock Futures Point to Slightly Higher Wall Street Open 12.04.12 | 09:12 am
- Stocks to Watch: Oracle, Geron, Knight, Big Lots (Update 1) 12.04.12 | 07:12 am
- Morning Briefing: 10 Things You Should Know 12.04.12 | 06:12 am
- A Weak Open On Wall Street As China Stumbles 09.10.12 | 04:09 pm
- Geron's CEO Presents At Update On Imetelstat Clinical Development Program Conference (Transcript) 09.10.12 | 02:09 pm
- Geron Stung by Cancer Drug Blowup 09.10.12 | 08:09 am
- 5 Biotech Stocks Under $5 Blasting Off 08.16.12 | 03:08 pm
Press Releases for GERN
- Geron Initiates Phase 2 Trial Of GRN1005 In Brain Metastases From Breast Cancer - Business Wire 12.12.11 | 07:12 am
- Geron Presents Final Phase 1 Clinical Data On GRN1005 At AACR-NCI-EORTC - Business Wire 11.15.11 | 07:11 am
- Geron To Focus On Its Novel Cancer Programs - Business Wire 11.14.11 | 04:11 pm
- Geron Corporation Reports 2011 Third Quarter Financial Results And Events - Business Wire 11.03.11 | 04:11 pm
- Geron Announces Conference Call To Discuss Third Quarter Financial Results And Highlights - Business Wire 10.25.11 | 04:10 pm
- Geron Announces Presentation At ECTRIMS/ACTRIMS - Business Wire 10.25.11 | 07:10 am
- Geron Presents Clinical Data Update From GRNOPC1 Spinal Cord Injury Trial - Business Wire 10.20.11 | 07:10 am
- Geron Corporation Appoints John A. Scarlett As Chief Executive Officer And Director - Business Wire 09.29.11 | 05:09 pm
- Geron To Webcast Presentations At Upcoming Investor Conferences - Business Wire 09.12.11 | 07:09 am
- Geron Corporation Reports 2011 Second Quarter Financial Results And Events - Business Wire 07.28.11 | 04:07 pm
Partner Headlines for GERN
- Morning Market Losers - Benzinga 12.04.12 | 09:12 am
- Geron Posts Narrower Loss - Analyst Blog - Zacks 10.31.12 | 09:10 am
- Neuralstem Swinging For The ALS Fences - Seeking Alpha 10.29.12 | 09:10 am
- Geron Hit by Pipeline Setback - Analyst Blog - NASDAQ 09.11.12 | 09:09 pm
- Morning Market Losers - Benzinga 09.10.12 | 09:09 am
- UPDATE: Stifel Nicolaus Initiates Geron Corporation at Buy with $4 PT; Oncology Refocus Paying Off - Benzinga 08.30.12 | 12:08 pm
- Geron Posts In-Line Loss - Analyst Blog - Zacks 08.01.12 | 09:08 am
- Ford and 3 Stocks INITIATED at These Levels Today - Wall St. Cheat Sheet 06.28.12 | 03:06 am
- Medgenics Moving In Record Time - Seeking Alpha 05.21.12 | 09:05 am
- Neutral on Geron Corp. - Analyst Blog - Zacks 04.02.12 | 07:04 pm
